Pulmonx Corporation
Healthcare sector | Medical Devices industry
Metrics for LUNG
| Price | $1.46 |
|---|---|
| Shares Outstanding | 42.24M |
| All-Time Low | $1.31 |
| 52-Week Low | $1.31 |
Balance Statement Metrics
| Net Cash / Share | $0 |
|---|---|
| Net Current Assets / Share | $0.63 |
| Net Tangible Assets / Share | $1.23 |
| Shares Outstanding Ave Change (Annual) | 2.51% |
| Shares Δ YoY | 3.3% |
| Avg CA Burn (Annual %) | -13.05% (as of 3-23-2026) |
| Avg CA Burn (Quarterly %) | -7.03% (as of 3-23-2026) |
Earning Metrics
| Max Earning Power / Share | $-2.08 |
|---|---|
| Adjusted Earning Power |
$-2.35
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
0.4%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 0 (as of 3-23-2026) |
| Avg EBITDA (5Q) | 0 (as of 3-23-2026) |
| Avg Net Income (5Y) | -56.2M (as of 3-23-2026) |
| Avg Net Income (5Q) | -13.4M (as of 3-23-2026) |
Indicators
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 3-23-2026 |
| Consecutive Years Paid | No | 3-23-2026 |
| Pays Dividend | No | 3-23-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 3-23-2026 |
| Net Income Positive | No | 3-23-2026 |
| Current Dividend Streak | No | 3-23-2026 |
Metric History Explorer
Pick a metric to view its history table and chart.
Tangible Book Value Per Share History
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $1.24 | 51.8M ($51,783,000) | 41.7M (41,673,648) |
| 2025-09-30 | Quarterly | $1.40 | 57.7M ($57,700,000) | 41.2M (41,246,534) |
| 2025-06-30 | Quarterly | $1.64 | 66.8M ($66,757,000) | 40.7M (40,743,806) |
| 2025-03-31 | Quarterly | $1.87 | 75.3M ($75,334,000) | 40.2M (40,247,480) |
| 2024-12-31 | Quarterly | $2.10 | 83.5M ($83,476,000) | 39.8M (39,785,969) |
| 2024-12-31 | Annual | $2.10 | 83.5M ($83,476,000) | 39.8M (39,785,969) |
| 2024-09-30 | Quarterly | $2.32 | 91.6M ($91,592,000) | 39.5M (39,487,879) |
| 2023-12-31 | Annual | $3.01 | 116M ($115,951,000) | 38.5M (38,516,383) |
| 2022-12-31 | Annual | $4.03 | 151.5M ($151,520,000) | 37.6M (37,555,565) |
| 2021-12-31 | Annual | $5.16 | 190.6M ($190,629,000) | 36.9M (36,931,762) |
Revenue History (Annual)
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 83.8M ($83,789,000) |
| 2023-12-31 | 68.7M ($68,675,000) |
| 2022-12-31 | 53.7M ($53,662,000) |
| 2021-12-31 | 48.4M ($48,416,000) |
Dividend Payments
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
Shares Outstanding Changes
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-03-18 | 42,237,203 | +990,169 |
Short Interest Changes
Latest short-interest change: 3,299,976 shares (11.26% of float) | Days to cover: 4.64
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-24 | 3,299,976 shares | -17,844 | -0.54% |
| 2026-03-12 | 3,317,820 shares | +37,682 | +1.15% |
| 2026-02-27 | 3,280,138 shares | +463,674 | +16.46% |
| 2026-02-11 | 2,816,464 shares | +183,280 | +6.96% |
Interesting Volume Days
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.